mitogen-activated protein kinase kinase 2
آخر تحديث 18 Aug 2020
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
ال MAP2K2 gene provides instructions for making a protein known as MEK2 protein kinase. This protein is part of a signaling pathway called the RAS/MAPK pathway, which transmits chemical signals from outside the cell to the cell's nucleus. RAS/MAPK signaling helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement, and the self-destruction of cells (apoptosis).
اختيارات الفيديو لـ Genesمكتبة الفيديو
Normal function
ال MAP2K2 gene provides instructions for making a protein known as MEK2 protein kinase. This protein is part of a signaling pathway called the RAS/MAPK pathway, which transmits chemical signals from outside the cell to the cell's nucleus. RAS/MAPK signaling helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement, and the self-destruction of cells (apoptosis).
ال MAP2K2 gene is very similar to a gene called MAP2K1, which provides instructions for making a protein known as MEK1 protein kinase. Like MEK2 protein kinase, this protein functions as part of the RAS/MAPK signaling pathway. Together, the MEK1 and MEK2 protein kinases appear to be essential for normal development before birth and for survival after birth.
Conditions referring to this gene or chromosome
Other names
dual specificity mitogen-activated protein kinase kinase 2
ERK activator kinase 2
MAP kinase kinase 2
MAPK-ERK Kinase 2
MAPK/ERK kinase 2
MAPKK2
MEK2
mitogen-activated protein kinase kinase 2, p45
MKK2
MP2K2_HUMAN
PRKMK2
Related patient information and medicines

Patient information leaflet
التليف النقوي
التليف النقوي which develops as a complication of other diseases is called secondary myelofibrosis. Myelofibrosis is caused by an abnormality of the developing cells (stem cells) in the bone marrow. It's not known what causes the genetic mutation in blood stem cells. The gene mutation that occurs in most people affected by myelofibrosis is a.

Patient information leaflet
ضمور العضلات
ضمور العضلات هو inherited (genetic) disorder causing muscle weakness. There are different types of muscular dystrophy, which vary as to how severe they are, ranging from very mild to severe. Also, if a child has delayed motor mil... MD may be diagnosed using one or more of the following tests: A blood test Blood tests for creatine kinase.

Patient information leaflet
التهاب المفاصل اليفعي مجهول السبب
As they are relatively new medicines, there are still studies being done to establish whether there are any long-term health risks from taking them. Options include: Etanercept Etanercept Tocilizumab Infliximab Abatacept Adalimumab Tofacitinib is another new drug. It belongs to a type of drug called JAK kinase inhibitors. It is sometimes used if.

Patient information leaflet
سرطان الكبد الأولي
If you already have cirrhosis and your health becomes worse quite quickly, the cause may be a liver السرطان which has developed. Everyone with cirrhosis should be having regular monitoring with an ultrasound and blood tests to detect any development of a liver cancer. There are new medicines being developed for the treatment of liver cancer. For.

Patient information leaflet
سرطان الفم
Diagnosing mouth cancer Your healthcare professional may suspect mouth cancer if you have a lesion in your mouth (such as a sore, an ... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that a person should receive a تشخيص or ruling out of cancer within 28 days of being.

Patient information leaflet
داء الخلايا البدينة واضطرابات الخلايا البدينة
A mast cell هو a type of white blood cell. If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on the immune system (suc... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new.
قراءة إضافية ومراجع
- mitogen-activated protein kinase kinase 2; MedlinePlus, National Library of Medicine.
- Duesbery N, Vande Woude G. BRAF and MEK mutations make a late entrance. Sci STKE. 2006 Mar 28;2006(328):pe15. doi: 10.1126/stke.3282006pe15.
- Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillessen-Kaesbach G, Wieczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A. 2007 Apr 15;143A(8):799-807. doi: 10.1002/ajmg.a.31658.
- Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, Heron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, Cave H. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. 2007 Dec;44(12):763-71. doi: 10.1136/jmg.2007.050450. Epub 2007 Aug 17.
- Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006 Mar 3;311(5765):1287-90. doi: 10.1126/science.1124642. Epub 2006 Jan 26.
- Scholl FA, Dumesic PA, Barragan DI, Harada K, Bissonauth V, Charron J, Khavari PA. Mek1/2 MAPK kinases are essential for Mammalian development, homeostasis, and Raf-induced hyperplasia. Dev Cell. 2007 Apr;12(4):615-29. doi: 10.1016/j.devcel.2007.03.009.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
18 Aug 2020 | أحدث إصدار
1 May 2012 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

